Roivant Sciences (ROIV) Current Deferred Revenue (2021 - 2025)
Roivant Sciences' (ROIV) quarterly Current Deferred Revenue came in at $1.2 million in Q1 2025, down 71.98% YoY from $4.2 million in Q1 2024, and down 61.54% on a QoQ basis from $3.0 million in Q4 2024.
Roivant Sciences (ROIV) Current Deferred Revenue (2021 - 2025) Analysis & Trends
Roivant Sciences (ROIV) has 5 years of Current Deferred Revenue data on file, last reported at $1.2 million in Q1 2025.
- Quarterly Current Deferred Revenue fell 71.98% year-over-year to $1.2 million in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $1.2 million (down 71.98% YoY) and the FY2025 annual result came in at $1.2 million, down 71.98% from the prior year.
- Current Deferred Revenue slipped to $1.2 million in Q1 2025, from $3.0 million in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $12.4 million in Q1 2023 to a low of $1.2 million in Q1 2025.
- A 5-year average of $6.4 million and a median of $5.9 million in 2021 frame the typical range for Current Deferred Revenue.
- Annual changes were most pronounced in 2022 — Current Deferred Revenue surged 71.46% — and 2024, when it plunged 74.83%.
- Tracing ROIV's Current Deferred Revenue over 5 years: stood at $5.9 million in 2021, then jumped by 31.73% to $7.8 million in 2022, then tumbled by 39.78% to $4.7 million in 2023, then sank by 35.31% to $3.0 million in 2024, then plunged by 61.54% to $1.2 million in 2025.
- The last three Current Deferred Revenue figures came in at $1.2 million (Q1 2025), $3.0 million (Q4 2024), and $3.4 million (Q3 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 1.17 Mn |
| Dec 31, 2024 | 3.04 Mn |
| Sep 30, 2024 | 3.41 Mn |
| Jun 30, 2024 | 2.66 Mn |
| Mar 31, 2024 | 4.17 Mn |
| Dec 31, 2023 | 4.70 Mn |
| Sep 30, 2023 | 5.80 Mn |
| Jun 30, 2023 | 10.57 Mn |
| Mar 31, 2023 | 12.44 Mn |
| Dec 31, 2022 | 7.80 Mn |
| Sep 30, 2022 | 8.37 Mn |
| Jun 30, 2022 | 9.01 Mn |
| Mar 31, 2022 | 10.15 Mn |
| Mar 31, 2021 | 5.92 Mn |